Black Diamond Therapeutics Croissance future

Future contrôle des critères 0/6

Les bénéfices de Black Diamond Therapeutics devraient diminuer de 12.7% par an tandis que son chiffre d'affaires annuel devrait croître de 89.6% par an. Le BPA devrait croître de en baisse de 1.1% par an.

Informations clés

-12.7%

Taux de croissance des bénéfices

-1.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	89.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	06 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Oct 30

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 08

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11

Black Diamond Therapeutics EPS misses by $0.16

May 07

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Jan 05

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Dec 01

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:BDTX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	3	-113	-116	-97	6
12/31/2025	N/A	-82	-53	-69	7
12/31/2024	N/A	-71	-66	-63	7
9/30/2024	N/A	-73	-61	-61	N/A
6/30/2024	N/A	-81	-68	-68	N/A
3/31/2024	N/A	-80	-68	-68	N/A
12/31/2023	N/A	-82	-67	-67	N/A
9/30/2023	N/A	-84	-75	-75	N/A
6/30/2023	N/A	-83	-73	-73	N/A
3/31/2023	N/A	-87	-77	-77	N/A
12/31/2022	N/A	-91	-85	-85	N/A
9/30/2022	N/A	-96	-88	-87	N/A
6/30/2022	N/A	-109	-99	-97	N/A
3/31/2022	N/A	-121	-107	-104	N/A
12/31/2021	N/A	-126	-103	-100	N/A
9/30/2021	N/A	-122	-94	-92	N/A
6/30/2021	N/A	-105	-78	-77	N/A
3/31/2021	N/A	-85	-65	-65	N/A
12/31/2020	N/A	-67	-52	-52	N/A
9/30/2020	N/A	-55	-44	-44	N/A
6/30/2020	N/A	-46	-38	-38	N/A
3/31/2020	N/A	-44	-29	-29	N/A
12/31/2019	N/A	-35	-25	-25	N/A
9/30/2019	N/A	-28	-20	-20	N/A
6/30/2019	N/A	-22	-16	-16	N/A
3/31/2019	N/A	-11	-13	-13	N/A
12/31/2018	N/A	-9	-9	-8	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: BDTX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: BDTX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: BDTX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: BDTX ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: BDTX ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de BDTX devrait être élevé dans 3 ans

Black Diamond Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.1% to US$13.83

Price target increased by 9.4% to US$11.60

Price target increased by 38% to US$9.33

Price target decreased to US$7.00

Price target decreased to US$8.00

Price target decreased to US$21.60

Recent updates

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Black Diamond Therapeutics, Inc. Announces Termination of Fang Ni, Pharm. D. as Chief Financial Officer

Black Diamond Therapeutics, Inc. Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients

Price target increased by 8.1% to US$13.83

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Co-Founder & Director notifies of intention to sell stock

New major risk - Shareholder dilution

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

Black Diamond Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Price target increased by 9.4% to US$11.60

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics, Inc. Announces Resignation of Rajeev Shah from Board of Directors, Including as A Member of the Audit Committee of the Board

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

New minor risk - Share price stability

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

New minor risk - Market cap size

Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Black Diamond Therapeutics, Inc. Announces Chief Executive Officer Changes

Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

New major risk - Financial position

New minor risk - Shareholder dilution

New major risk - Share price stability

Black Diamond Therapeutics, Inc. Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Price target increased by 38% to US$9.33

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Key Executive recently bought US$72k worth of stock

Black Diamond Therapeutics, Inc. Announces Changes to Board of Directors

High number of new directors

Black Diamond Therapeutics, Inc. Appoints as Melanie Morrison as Senior Vice President, Development Operations

Black Diamond Therapeutics, Inc. Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Price target decreased to US$7.00

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Key Executive recently bought US$61k worth of stock

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Index

Black Diamond Therapeutics Appoints Sergey Yurasov as Chief Medical Officer

High number of new directors

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

Price target decreased to US$8.00

High number of new directors

Black Diamond Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of BDTX-1535

Black Diamond Therapeutics, Inc. Announces Board Changes

Price target decreased to US$21.60

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

Executive Officer Thomas Leggett has left the company

Price target decreased to US$42.83

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from Russell 2500 Growth Index

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Black Diamond Therapeutics, Inc. Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

COO & General Counsel exercised options and sold US$99k worth of stock

Black Diamond Therapeutics EPS misses by $0.16

COO & General Counsel exercised options and sold US$89k worth of stock

COO & General Counsel exercised options and sold US$94k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

COO & General Counsel exercised options and sold US$98k worth of stock

Diamond Therapeutics Signs Agreement with McGill University for Research on Low-Dose LSD

Black Diamond Therapeutics, Inc. Appoints Kapil Dhingra to Board of Directors

New 90-day low: US$28.62

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Co-Founder notifies of intention to sell stock

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Black Diamond Therapeutics, Inc. Provides Update on Gbm Program and Presents Pre-Clinical Data At the 2020 Sno Annual Meeting